Big pharma-backed AdvanCell pockets $315m to progress RLT to Phase III - Pharmaceutical Technology

AdvanCell will use the mega-round earnings to progress ADVC001 and build radiopharmaceutical manufacturing infrastructure. The radiopharma specialist will use earnings from this mega-round to progress ADVC001 and build manufacturing infrastructure to prepare for potential commercialisation. AdvanCell will use the funds to progress its lead radiopharmaceutical to Phase III and enhance its US manufacturing capacity. Credit: Chayanit / Shutterstock.com. Radiopharmaceutical specialist AdvanCell has banked $315m in an upsized Series D financing to take its prostate cancer therapy to registrational trials, while gearing itself up for the drug’s potential commercialisation. The oversubscribed funding round, which was co-led by Ally Bridge Group and…

Source: Pharmaceutical Technology